Pharmacokinetic and Pharmacodynamic Drug Interactions With New Oral Anticoagulants

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Annals of Pharmacotherapy

• Publication date

  2013-10-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1060028013504741PMID 24259602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

  2013cited by this paper
• New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

  2013cited by this paper
• Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

  2013cited by this paper
• Apixaban versus Warfarin in Patients with Atrial Fibrillation

  2012influential reference
• An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation

  2012influential reference
• Rivaroxaban in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban

  2011cited by this paper
• Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

  2011cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban

  2011cited by this paper
• Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness

  2011influential reference
• Apixaban with antiplatelet therapy after acute coronary syndrome.

  2011influential reference
• Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

  2011influential reference
• Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

  2009cited by this paper
• In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans

  2009influential reference
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor

  2009cited by this paper
• Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

  2009cited by this paper
• Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009influential reference
• Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial

  2009influential reference
• Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

  2008influential reference
• Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict.

  2008cited by this paper
• Guidelines for the Management of Patients With Atrial Fibrillation

  2006cited by this paper
• Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

  2006cited by this paper
• Pharmacokinetics and metabolic drug interactions.

  2006cited by this paper
• Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin

  2006cited by this paper
• Functional interactions between P-glycoprotein and CYP3A in drug metabolism

  2005influential reference
• Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor

  2005influential reference
• Reviewing the reality: why we need to change

  2005cited by this paper
• Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

  2005cited by this paper
• Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

  2001cited by this paper

• Antiandrogen therapies: Management of drug interactions with anticoagulation.

  2025cites this paper
• PK/PD interactions of antiarrhythmic drugs and oral anticoagulants in atrial fibrillation patients: clinical implications for stroke and dementia prevention

  2025cites this paper
• Evaluation of direct oral anticoagulant continuation versus switching to a parenteral anticoagulant in critically ill patients: a retrospective cohort study

  2025cites this paper
• Evaluating Major Bleeding Risks with Concomitant Use of Direct Oral Anticoagulants and Selective Serotonin Reuptake Inhibitors in Nonvalvular Atrial Fibrillation Patients

  2025influential citation
• Potential interactions between antimicrobials and direct oral anticoagulants: population-based cohort and case-crossover study.

  2025cites this paper
• Evaluation of the Impact of Orange Juice on Apixaban Pharmacokinetics in Healthy Rats

  2024cites this paper
• Anticoagulation and antiplatelet therapy in short bowel syndrome: A systematic review

  2024cites this paper
• Potential interactions between direct oral anticoagulants and atorvastatin/simvastatin: a cohort and case-crossover study

  2024cites this paper
• Treatment of Cancer-Associated Thrombosis: An Update

  2024cites this paper
• The pharmacokinetics of dabigatran in a rat model of hyperlipidaemia induced by poloxamer 407

  2024cites this paper
• Anticoagulation in Chronic Kidney Disease

  2024cites this paper
• Evidence of potential pro‐haemorrhagic drug interactions between CYP3A4 inhibitors and direct oral anticoagulants: Analysis of the FAERS database

  2023cites this paper
• Pre-hospital use of direct oral anticoagulants agents is associated with a lower risk of major bleeding events in critically ill patients: A single academic center experience.

  2023cites this paper
• Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis

  2023cites this paper
• Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database

  2023cites this paper
• [Human immunodeficiency virus and venous thromboembolism: Role of direct oral anticoagulants].

  2023cites this paper
• Atraumatic splenic rupture in a patient treated with rivaroxaban: A case report and a narrative review

  2022cites this paper
• Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation.

  2022cites this paper
• Association between concurrent use of diltiazem and DOACs and risk of bleeding in atrial fibrillation patients

  2022cites this paper
• Bleeding events among patients concomitantly treated with direct oral anticoagulants and macrolide or fluoroquinolone antibiotics

  2022cites this paper
• Important Risk Factors in Patients with Nonvalvular Atrial Fibrillation Taking Dabigatran Using Integrated Machine Learning Scheme—A Post Hoc Analysis

  2022cites this paper
• Simultaneous Determination of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Human Blood Serum by HPLC-MS/MS for Therapeutic Drug Monitoring

  2022cites this paper
• Direct oral anticoagulants versus warfarin for secondary prevention of cerebral infarction and bleeding in older adults with atrial fibrillation

  2022cites this paper
• Practical Treatment Guidance for Cancer-Associated Thrombosis - Managing the Challenging Patient: A Consensus Statement.

  2022cites this paper
• Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults With Atrial Fibrillation

  2021cites this paper
• Off-Label Direct Oral Anticoagulant Dosing: Caution Advised.

  2021cites this paper
• Use of direct oral anticoagulants in ICU patients. Part I - Applied pharmacology.

  2021cites this paper
• Rapid simultaneous clinical monitoring of five oral anti-coagulant drugs in human urine using green microextraction technique coupled with LC–MS/MS

  2021cites this paper
• The Comparative Effectiveness and Safety of Different Anticoagulation Strategies for Treatment of Left Atrial Appendage Thrombus in the Setting of Chronic Anticoagulation for Atrial Fibrillation or Flutter

  2021cites this paper
• Association Between Use of Pharmacokinetic‐Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case‐Control Study

  2021cites this paper
• Prescribing of two potentially interacting cardiovascular medications in atrial fibrillation patients on direct oral anticoagulants

  2021cites this paper
• Naringenin has an inhibitory effect on rivaroxaban in rats both in vitro and in vivo

  2021cites this paper
• Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption

  2021cites this paper
• Pulmonary Disease, Pulmonary Hypertension and Atrial Fibrillation.

  2021cites this paper
• Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function

  2020cites this paper
• Revisión sistemática y metanálisis del tratamiento anticoagulante en la trombosis asociada al cáncer. Implicaciones en estudios de no inferioridad

  2020cites this paper
• Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

  2020cites this paper
• The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: A systematic review.

  2020cites this paper
• Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose

  2020cites this paper
• Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms

  2020cites this paper
• Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports

  2020cites this paper
• Direct oral anticoagulants in patients with hematologic malignancies

  2020cites this paper
• Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese

  2020cites this paper
• [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].

  2020cites this paper
• Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants

  2019cites this paper
• Direct Oral Anticoagulants

  2019cites this paper
• Safety and efficacy of direct oral anticoagulants for venous thromboembolism and stroke prophylaxis in patients with hematologic malignancies

  2019cites this paper
• Anticoagulant Medications for the Prevention and Treatment of Thromboembolism.

  2019cites this paper
• Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation

  2019cites this paper
• Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS)

  2019cites this paper
• Clinically relevant drug interactions between newer antidepressants and oral anticoagulants

  2019cites this paper
• Optimální léčba žilního tromboembolismu

  2018cites this paper
• Management of cancer-associated venous thromboembolism - a case-based practical approach.

  2018cites this paper
• Use of direct oral anticoagulants in daily practice.

  2018cites this paper
• Lékové interakce warfarinu a nových, přímých orálních antikoagulancií

  2018cites this paper
• Optimal treatment of venous thromboembolism

  2018cites this paper
• Pharmacokinetic Interactions between Concomitantly Administered Phenytoin with Rivaroxaban

  2018cites this paper
• Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management.

  2018cites this paper
• Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients

  2018cites this paper
• Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines

  2018cites this paper
• Drug-drug interactions of warfarin and new direct oral anticoagulans

  2018cites this paper
• Spontaneous splenic rupture due to rivaroxaban

  2018cites this paper
• CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis

  2018cites this paper
• HPLC-MS/MS Method for Determining Dabigatran in Human Blood Serum

  2018cites this paper
• DRUG UTILIZATION EVALUATION AND ASSESSMENT OF ECONOMIC BURDEN OF ANTICOAGULANTS IN A TERTIARY CARE HOSPITAL IN SOUTH INDIA

  2018cites this paper
• Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact

  2017cites this paper
• Decreased Rivaroxaban Levels in a Patient with Cerebral Vein Thrombosis Receiving Phenytoin

  2017cites this paper
• Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions.

  2017cites this paper
• Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs

  2017cites this paper
• Management of Direct Oral Anticoagulants with Mixed P-gp/3A4 Drug-Drug Interactions

  2017cites this paper
• Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism

  2017cites this paper
• POSTUPNICI ZA PERIPROCEDURALNO ZBRINJAVANJE I ZBRINJAVANJE KRVARENJA U BOLESNIKA LIJEČENIH NOVIM ORALNIM ANTIKOAGULANTNIM LIJEKOVIMA

  2017cites this paper
• Potential drug–drug interactions with direct oral anticoagulants in elderly hospitalized patients

  2017cites this paper
• Gold nanoparticles based sensor for in vitro analysis of drug-drug interactions using imipramine and isoniazid drugs: A proof of concept approach

  2017cites this paper
• Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa

  2017cites this paper
• The effects of dietary and herbal phytochemicals on drug transporters☆

  2017cites this paper
• Apixaban Concentration with and without Coadministration of Carbamazepine: A Case with No Apparent Interaction.

  2017cites this paper
• Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs.

  2016cites this paper
• Major bleeding complications in patients treated with direct oral anticoagulants: One-year observational study in a Paris Hospital.

  2016cites this paper
• The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use

  2016cites this paper
• Direct oral anticoagulants: a guide for daily practice.

  2016cites this paper
• Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics.

  2016cites this paper
• Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.

  2016cites this paper
• Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.

  2016cites this paper
• Placental Pharmacology---Implications for Therapy in Pregnancy

  2016cites this paper
• Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation.

  2016cites this paper
• Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism

  2016cites this paper
• Spontaneous rectus sheath hematoma in a patient treated with apixaban.

  2016cites this paper
• Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects

  2016cites this paper
• Novel Oral Anticoagulants for the Treatment of Venous Thromboembolism in Cancer Patients

  2016cites this paper
• Drug-drug interactions related to altered absorption and plasma protein binding: theoretical and regulatory considerations, and an industry perspective.

  2015cites this paper
• Direct Oral Anticoagulants

  2015cites this paper
• How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation

  2015cites this paper
• Analgesic use before and after oral anticoagulant initiation—a population-based study in Finland

  2015cites this paper
• How to Manage an Anticoagulated Patient in Case of Drug-Drug Interaction?

  2015cites this paper
• Checklists for the use of novel oral anticoagulants by the front-line clinician

  2015cites this paper
• [Which place for direct oral anticoagulants in routine hospital medical practice?].

  2015cites this paper
• A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products

  2015cites this paper
• Hammastoimenpiteet suoria antikoagulantteja käyttävällä potilaalla

  2015cites this paper
• Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.

  2015cites this paper